Fda agrees with galmed's plan to use aramchol meglumine in the randomized double-blind placebo-controlled part of the phase 3 armor study

Tel aviv, israel, aug. 2, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the fda agreed with its plan to use aramchol meglumine (in lieu of aramchol free acid) in its phase 3 armor study without the need to conduct additional nonclinical and clinical studies other than planned limited pharmacology studies relating to aramchol meglumine.
GLMD Ratings Summary
GLMD Quant Ranking